Metabolic reprogramming and epigenetic modifications are hallmarks of cancer cells. In
cancer cells, metabolic pathway activity varies during tumorigenesis and cancer …

Abstract Divergent N6-methyladenosine (m6A) modifications are dynamic and reversible
posttranscriptional RNA modifications that are mediated by m6A regulators or m6A RNA …

Background & Aims RNA N 6-methyladenosine (m 6 A) reader protein YTHDF1 has been
implicated in cancer; however, its role in hepatocellular carcinoma (HCC), especially in non …

Cancer immunotherapy, especially immune checkpoint therapy, has revolutionized
therapeutic options by reactivating the host immune system. However, the efficacy varies …

Background Pathological cardiac hypertrophy is a major contributor of heart failure (HF),
which seriously threatens human's health world widely. Deregulation of m6A RNA …

An immunosuppressive state is a typical feature of the tumor microenvironment. Despite the
dramatic success of immune checkpoint inhibitor (ICI) therapy in preventing tumor cell …

The epigenetic modification of tumorigenesis and progression in neoplasm has been
demonstrated in recent studies. Nevertheless, the underlying association of N7 …

Aspergillus flavus and its toxic aflatoxins secondary metabolites contaminate food and
grains, posing a severe threat to human health and leading to liver cancer. Here, we …

Epitranscriptomic remodeling such as N6‐methyladenosine (m6A) modification plays a
critical role in tumor development. However, little is known about the underlying …

Background Energy balance has long been known to extend lifespans and inhibit
carcinogenesis in multiple species by slowing age‐related epigenetic changes while the …